共 317 条
[1]
Corless CL(2014)Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32 1563-70
[2]
Ballman KV(2007)Surgical resection of gastrointestinal stromal tumors after treatment with imatinib Annals of surgical oncology. 14 14-24
[3]
Antonescu CR(2007)Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain European journal of cancer. 43 144-8
[4]
Kolesnikova V(2007)Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Annals of surgery. 245 347-52
[5]
Maki RG(2009)Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665 Journal of surgical oncology. 99 42-7
[6]
Pisters PW(2012)Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial Int J Surg Oncol. 2012 761576-80
[7]
Blackstein ME(2012)Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132 Annals of surgical oncology. 19 1074-43
[8]
Blanke CD(2013)Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience Annals of surgical oncology. 20 2937-49
[9]
Demetri GD(2014)Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients Journal of the American College of Surgeons. 219 439-9
[10]
Heinrich MC(2014)Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib—analysis of prognostic factors (EORTC-STBSG collaborative study) Eur J Surg Oncol. 40 412-32